Data / Drug companies / Amlodipine and atorvastatin
Amlodipine and atorvastatin: 9 companies and 72 products in the FDA NDC directory
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Amlodipine and atorvastatin is listed in the FDA National Drug Code Directory by 9 companies, with 72 products in commercial distribution. 45 of the products (62.5%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are tablet, film coated; tablet, coated, and the newest product started marketing on September 28, 2026.
The request: Get every company that lists amlodipine and atorvastatin in the FDA NDC directory, with headquarters, website and number of employees. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 9
- Products
- 72
- Generic (ANDA) products
- 45 (62.5%)
- Application numbers
- 4
- Routes
- Oral
- Brand names
- Caduet
- openFDA record search
- api.fda.gov
Companies that list amlodipine and atorvastatin
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Alembic Pharmaceuticals Inc. | 11 | tablet, film coated | Generic drugs (ANDA) | May 23, 2025 |
| Alembic Pharmaceuticals Limited | 11 | tablet, film coated | Generic drugs (ANDA) | May 23, 2025 |
| Prasco Laboratories | 11 | tablet, coated | Authorized generics (NDA) | March 14, 2022 |
| Apotex Corp. | 8 | tablet, film coated | Generic drugs (ANDA) | July 29, 2020 |
| Mylan Pharmaceuticals Inc. | 8 | tablet, film coated | Generic drugs (ANDA) | April 2, 2015 |
| Pfizer Laboratories Div Pfizer Inc | 8 | tablet, film coated | New drug applications (NDA) | August 31, 2022 |
| Viatris Specialty LLC | 8 | tablet, film coated | New drug applications (NDA) | September 28, 2026 |
| Bryant Ranch Prepack | 5 | tablet, film coated | Generic drugs (ANDA) | July 29, 2020 |
| Bryant Ranch Prepack | 2 | tablet, film coated | Generic drugs (ANDA) | July 29, 2020 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated | 61 | 84.7% |
| Tablet, coated | 11 | 15.3% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 45 | 62.5% |
| New drug applications (NDA) | 16 | 22.2% |
| Authorized generics (NDA) | 11 | 15.3% |
Pharmacologic classes
| Class | Products |
|---|---|
| Calcium Channel Blocker | 72 |
| Dihydropyridine Calcium Channel Blocker | 72 |
| HMG-CoA Reductase Inhibitor | 72 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.